文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

全球前列腺癌、膀胱癌与肾癌的发病率、死亡率及风险归因死亡趋势:GBD 2021系统分析

Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021.
PubMed 文献 · Eur Urol Oncol · 2025-05-28

本研究基于GBD 2021数据,分析全球前列腺癌、膀胱癌和肾癌的年龄标化发病率(ASIR)与死亡率(ASDR)趋势。2000至2021年肾癌ASIR上升(AAPC 0.15%),膀胱癌和前列腺癌ASIR下降;三种癌症ASDR均下降,膀胱癌降幅最大(AAPC -1.02%)。吸烟和高BMI是风险归因死亡的主要原因。

要点

  • 2000至2021年肾癌ASIR上升(AAPC 0.15%),膀胱癌和前列腺癌ASIR下降。
  • 三种癌症ASDR均下降,膀胱癌降幅最大(AAPC -1.02%)。

核心结论

  • GBD 2021显示三种泌尿系统肿瘤的发病和死亡负担仍显著,需针对早期筛查和可干预风险因素制定公共卫生策略。

研究设计与样本

  • 基于GBD 2021数据库的全球疾病负担系统分析,按性别、地区和社会人口指数(SDI)计算年龄标化发病率和死亡率。

主要发现

  • 前列腺癌发病和死亡负担最高,其次为膀胱癌和肾癌。
  • 2000至2021年肾癌ASIR上升(AAPC 0.15%,95%CI 0.07-0.23%),膀胱癌ASIR下降(AAPC -0.48%,95%CI -0.54%至-0.43%),前列腺癌ASIR下降(AAPC -0.12%,95%CI -0.24%至-0.01%)。
  • 三种癌症ASDR均下降,膀胱癌降幅最大(AAPC -1.02%,95%CI -1.08至-0.97%)。
  • 高SDI至中SDI地区发病率较高,吸烟和高体重指数是风险归因死亡的主要原因。

临床怎么用

  • 关注肾癌发病率上升趋势,加强高危人群筛查。
  • 针对吸烟和高BMI等可干预风险因素开展防控。
  • 在高中SDI地区优化早期检测策略以降低疾病负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Bladder cancer (BCa), kidney cancer (renal cell carcinoma [RCC]), and prostate cancer (PCa) altogether contribute remarkably to global cancer morbidity and mortality. However, comprehensive global assessments of their incidence and mortality trends are lacking. This study aimed to assess the global, regional, and national burden of the urological cancers using the most updated data from the Global Burden of Disease (GBD) 2021 study. METHODS: Data on these urological cancers were extracted from the GBD 2021 database. Age-standardized incidence rates (ASIRs) and age-standardized death rates (ASDRs) were calculated by sex, region, and sociodemographic index (SDI). KEY FINDINGS AND LIMITATIONS: In 2021, there were 2.25 million new cases and 815 546 deaths from urological cancers globally. PCa had the highest incidence and mortality burden, followed by BCa and RCC. From 2000 to 2021, ASIR increased for RCC (average annual percent change [AAPC]: 0.15%, 95% confidence interval [CI] 0.07-0.23%), while it declined for BCa (AAPC: -0.48%, 95% CI -0.54% to -0.43%) and PCa (AAPC: -0.12%, 95% CI -0.24% to -0.01%). ASDRs decreased for all three cancers, with BCa showing the largest reduction (AAPC: -1.02%, 95% CI -1.08 to -0.97%). The incidences were higher in high- to middle-SDI regions. Smoking and a high body mass index were the leading causes of risk-attributable deaths of urological cancers. CONCLUSIONS AND CLINICAL IMPLICATIONS: The GBD 2021 study revealed that the incidences and mortality burden of these urological cancers remained significant. Public health strategies targeting early detection and modifiable risk factors are crucial to further reduce the evolving burden of these cancers.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Leung DK, Wong CH, Ko IC, et al. Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021. Eur Urol Oncol. 2025. PMID: 40441940. doi:10.1016/j.euo.2025.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。